Letrozol Viatris

Letrozole, the active ingredient in Letrozol Viatris, is an aromatase inhibitor presented as a oral tablet for oral use. It treats postmenopausal hormone receptor‑positive breast cancer in adjuvant, neoadjuvant and metastatic settings.

GNH USA supplies Letrozol Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Letrozol Viatris is an aromatase inhibitor used in the management of hormone‑dependent breast cancer. - Postmenopausal hormone receptor‑positive breast cancer (adjuvant): reduces recurrence risk after surgery. - Metastatic hormone receptor‑positive breast cancer: controls disease progression in advanced stages. - Neoadjuvant therapy for postmenopausal breast cancer: shrinks tumors before surgical removal.

Letrozol Viatris may cause a range of adverse reactions.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness. - Nausea: upset stomach or urge to vomit. - Headache: mild to moderate pain. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Deep vein thrombosis: painful swelling in the leg. - Pulmonary embolism: sudden shortness of breath. - Severe liver injury: jaundice or elevated liver enzymes. - Bone fracture: increased risk due to lowered estrogen. - Myocardial infarction: chest pain indicative of heart attack. - Anaphylaxis: severe allergic reaction with rash, swelling, or breathing difficulty.

Patients receiving Letrozol Viatris should be monitored for several safety considerations. - Monitor bone mineral density: assess osteoporosis risk and consider calcium/vitamin D supplementation. - Assess cardiovascular risk: evaluate history of thromboembolic events before initiating therapy. - Check liver function: perform baseline and periodic liver enzyme tests. - Avoid use in premenopausal women: drug is ineffective and may cause harm. - Pregnancy and lactation: contraindicated; ensure effective contraception. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Letrozol Viatris can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with estrogen replacement therapy: may negate drug effect. - Strong CYP2A6 inducers (e.g., rifampin): may reduce plasma levels. - Strong CYP2A6 inhibitors (e.g., ketoconazole): may increase exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may increase bleeding risk. - Tamoxifen: potential antagonistic effect on estrogen pathways. - CYP2A6 substrates (e.g., nicotine): may require dose adjustment.